The first participant has been dosed in a Phase 1 trial testing F230 for the treatment of pulmonary arterial hypertension.

Meta CEO Mark Zuckerberg is now taking personal control of a bold and secretive mission: building a superintelligent AI that ...

El Paso County Commissioners have approved a recommendation from the El Paso Transportation Authority (ETA) to eliminate ...

Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across ...

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Investor Contact: David ...